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a b s t r a c t
Despite remarkable progress in diagnosis and understanding of risk factors, cardiovascular disease (CVD)
remains still the leading cause of morbidity and mortality in the world’s developed countries. The
metabolic syndrome, a cluster of risk factors (visceral obesity, insulin resistance, dyslipidaemia, andhyper-
tension), is increasingly being recognized as a new risk factor for type 2 diabetes and atherosclerotic
cardiovascular disease. Nevertheless, there is wide variation in both the occurrence of disease and age of
onset, even in individuals who display very similar risk proﬁles. There is now compelling evidence that
a complex interplay between genetic determinants and environmental factors (still largely unknown) is
the reason for this large inter-individual variation in disease susceptibility. The purpose of the present
review is to describe the current status of our knowledge concerning the gene–environment interactions
potentially implicated in the pathogenesis of metabolic syndrome, diabetes and cardiovascular disease. It
focuses predominantly on studies of genes (peroxisome proliferator-activated receptor-gamma, alcohol
dehydrogenase type 1C, apolipoprotein E, glutathione S-transferases T1 and M1) that are known to be
modiﬁed by dietary and lifestyle habits (fat diet, intake of alcohol and smoking habit). It also describes
the limited current understanding of the role of genetic variants of xenobiotic metabolizing enzymes
and their interactions with environmental toxicants. Additional studies are needed in order to clarify
whether inter-individual differences in detoxiﬁcation of environmental toxicants may have an essential
role in the development of CVD and contribute to the emerging ﬁeld of “environmental cardiology”. Such
knowledge may be particularly relevant for improving cardiovascular risk stratiﬁcation and conceiving
the development of “personalized intervention program”.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The AmericanHeart Association reports that cardiovascular dis-
ease (CVD) is the leading cause of death in the United States and
the cause of more than half of all mortality in the world’s devel-
oped countries [1]. Major clinical manifestations of cardiovascular
disease include myocardial infarction, coronary artery disease,
stroke, peripheral artery disease and congestive heart failure. In
most cases, these clinical conditions result from atherosclerosis,
a progressive disease of the arterial wall, characterized by focal
thickening and luminal obstruction [2].
Much of the actual knowledge about CVD was obtained by
the very well planned longitudinal, initiated in 1948, Framingham
Heart study [3]. The Framinghamgroup has coined the termof “risk
factor, and has contributed enormously to the understanding of the
underlying pathologic process leading to CVD. Major well-known
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risk factors include hypertension, elevated levels of low-density
lipoprotein cholesterol (LDL-C), smoking, and type-2 diabetes.
In addition, the joint occurrence, or ‘clustering’ of multiple
metabolic abnormalities has recently led to the introduction of the
concept (from Greek meaning “running together”) of the metabolic
syndrome (MS) [4,5]. This syndrome is associatedwith an increased
risk of type 2 diabetes, accelerated atherosclerosis and cardiovas-
cular events.
Despite advances in pathophysiology and risk factors that pre-
dispose to CHD, there are many key aspects that remain unclear.
These include variation in susceptibility, and a wide variable age of
onset in individuals who display very similar risk proﬁles.
These differences are mainly attributed to genetic differences
or to interactions between genes and environmental factors [6].
However, the polygenic nature of metabolic syndrome and related
cardiovascular risk suggests that it is unlikely that a single gene is
responsible for the development of the disease. It is more plau-
sible that are many genes each of small effect displaying effect
modiﬁcation in the presence of certain environmental factors (e.g.
cholesterol, tobacco and alcohol).
0027-5107/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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Table 1
Diagnostic criteria for metabolic syndrome.
Abdominal obesity
(waist circumference)
Men≥102 cm (≥40 in.)
women≥88 cm (≥35 in.)
Elevated triglycerides ≥150mg/dl (1.7mmol/l)
Reduced HDL-C Men<40mg/dl (0.9mmol/l)
women<50mg/dl (1.1mmol/l)
Blood pressure ≥130 systolic blood pressure
≥85mmHg diastolic blood
pressure
High fasting glucose 110mg/dL and <126mg/dL
(without diabetes)
The purpose of the present review is to describe the cur-
rent knowledge concerning the gene–environment interactions
potentially implicated in the pathogenesis of metabolic syndrome,
diabetes and cardiovascular disease.
2. Atherogenesis in metabolic syndrome and type 2
diabetes
The clinical characteristics of the MS include insulin resistance,
dyslipidaemia, abdominal obesity and hypertension. Any three of
the ﬁve criteria reported in Table 1 constitute a diagnosis of MS.
The increasing prevalence of MS worldwide seems to be due
largely bymoreobesity that is promoted andexacerbatedby seden-
tary lifestyles. The MS is a powerful and prevalent predictor of
diabetes and atherosclerotic cardiovascular events [7]. Adipose tis-
sue plays a vital role in the pathogenesis of the MS, promoting
the development of type 2 diabetes mellitus and atherosclero-
sis. Abdominal fat associated is a major source of the excessive
ﬂux of free fatty acids (FFAs), which are known to affect insulin
signal transduction pathway, induce endothelial dysfunction due
to increased reactive oxygen species (ROS) generation and oxida-
tive stress [7]. Prolonged release of FFAs is implicated in the
development diabetes since it promotes insulin resistance and the
associated loss of pancreatic beta-cell function (Fig. 1).
Insulin resistance is also itself a risk factor for CVD. It blunts
vascular production of nitric oxide, a factor crucial to the normal
vasodilatory response and endothelial function [8].
Moreover, glucose intolerance and hyperglycemia facilitate the
accelerated formation of advanced glycation endproducts (AGEs),
that are a heterogeneous group of molecules formed from the
nonenzymatic reaction of reducing sugars with free amino groups
of proteins, lipids, and nucleic acids. AGEs interact with receptor
for advanced glycation endproducts (RAGE) to activate numerous
intracellular signaling pathways implicated in the atherosclerotic
pathway [9,10].
Numerous animal and human studies have shown that AGEs
and their receptors critically contribute to amplify inﬂamma-
tory responses through enhanced generation of proinﬂammatory
adhesion molecules, cytokines, and tissue-destructive matrix met-
alloproteinases [11]. In addition to those endogenously formed,
AGEs can also be introduced in the body from exogenous sources.
For instance, tobacco smoke is a well-known exogenous source
of AGEs [12]. Furthermore, diet is an important source of exoge-
nous AGEs, with the highest content found in heat-treated foods
[13].
Moreover, studies indiabetic subjectsdemonstrated thatdietary
AGEs increase markers of inﬂammation (C-reactive protein tumor
necrosis factor and endothelial dysfunction vascular cell adhesion
Fig. 1. Progression and outcomes of the metabolic syndrome. The metabolic syndrome arises largely by visceral obesity, and encompasses each stage in the development of
type 2 diabetes and atherosclerosis.
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molecule 1) whereas a restriction of dietary AGEs et led to suppres-
sion of all these markers [14].
Furthermore, visceral obesity is strongly associated with high
plasma triglycerides and low plasma high-density lipoprotein-
cholesterol (HDL-C), and with high plasma concentrations of
apolipoprotein B (apoB)-containing lipoproteins. Dyslipidemia
contributes to a proinﬂammatory state and atherosclerosis, that,
indeed, is considered a low-grade chronic inﬂammatory disease
[2]. Atherosclerotic lesion begins with “fatty streak” lesions in the
artery walls, due to the presence of inﬂammatory cells and the
accumulationof lipid-containing intimalmacrophages (foamcells).
Early lesions can continue to develop through several stages, ulti-
mately ending with a complex plaque accumulated in the artery
wall, which blocks blood ﬂow and can precipitate acute clinical
manifestations (Fig. 1).
Acute clinical events, such asmyocardial infarction or stroke, are
often the result of rupture or ulceration of an “unstable” or “vul-
nerable” plaque which do not appear severe on angiography. The
mechanisms responsible for plaque vulnerability remain, however,
poorly deﬁned. Inﬂammation, thrombosis and apoptosis across all
vascular cell type are seen to be key players in atherosclerotic
plaque instability and rupture [2,15].
The appearance of atherosclerotic lesions is generally similar in
patients with and without diabetes; however, patients with type 2
diabetes showmore advanced lesion development, and atheroscle-
rosis tend to be more diffuse and not focal [7].
The pathogenesis of atherosclerosis is closely related to molec-
ular mechanisms, including the modulation of oxidation-sensitive
signaling, the expression of cytokines and adhesion molecules, the
recruitment of macrophages and T cells, and the consequences of
chronic inﬂammatory conditions in general [2].
Furthermore, there is now accumulating evidence that supports
a critical role for DNA damage and telomere dysfunction in the
atherogenic process, probably affecting the vascular function of
both endothelial and smooth muscle cells [16].
3. Genetic instability in vascular pathobiology: new
evidence for atherogenesis
Every cells are daily attacked by numerous genomic insults,
both from intracellular cellular metabolism and exposure to envi-
ronmental agents (e.g. ionizing radiation, chemicals and toxin
pollutants) capable of interacting with the DNA.
Indeed, it is well-known that DNA damage can occur in cells
exposed to oxidative stress. Several well-known atherosclerotic
risk factors are likely mediators of oxidative DNA damage [16]. For
instance, the peroxidation of lipids produces a variety of products
(e.g. epoxides, aldehydes, etc.), which are themselves reactive and
able to interact with DNA [17].
Metabolic syndrome induces an increase in oxidative stress and
may be one of the triggers for increased oxidative DNA damage
and telomere shortening of endothelial progenitor cells, promot-
ing endothelial dysfunction [18]. Furthermore, increased oxidative
DNAdamage in type 2 diabetes iswell documented, and it has been
suggested that itmaybe anuseful clinicalmarker in order topredict
complications associated with diabetes, such as microangiopathy
and macroangiopathy [19–23]. Recently, we have also found that
diabetes is one major determinant of chromosomal DNA damage
in patients with or without coronary artery disease [24].
This is consistent with a large body of evidence supporting the
notion thatoxidative stress-induced-genetic instability is a relevant
contributor of atherosclerotic plaque development and its compli-
cations [25–29].
At vascular level, the loss of heterozygosity and microsatellite
instability have been reported in DNA extracted from atheroscle-
rotic plaques, compared to DNA extracted from adjacent normal
Fig. 2. Simpliﬁed representation of the DNA damage response pathway. This pathway involves a highly complex DNA-damage response network, able to sense the damage,
then to transducer speciﬁc signals into cells, and ﬁnally to cause cell cycle arrest for ensuring DNA repair. If DNA damage is non-corrected by the DNA repair mechanisms, it
may lead to altered cellular functions. The cell cycle can be also blocked permanently, leading to a senescent state of the vascular cell or apoptosis.
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tissue, suggesting that speciﬁc molecular alteration of target genes
could be an important molecular mechanism associated to the
atherogenic process [30–33].
In addition, single or associated clonal chromosomal abnormali-
tieswere found inprimary cell cultures fromhumanatherosclerotic
plaques. More recently, Matturri et al. showed that unstable
atherosclerotic plaques presented a variety of chromosomal abnor-
malities in carotid endarterectomy specimens [34]. Conversely,
stable plaques did not present any chromosomal abnormalities,
supporting the hypothesis that genetic instability might be of par-
ticular importance in the mechanisms of plaque evolution.
DNA adducts have also been detected in SMCs of human
abdominal aorta affected by atherosclerosis, and their levels were
signiﬁcantly correlatedwithknownatherogenic risk factors includ-
ing age, number of currently smoked cigarettes, arterial pressure,
blood cholesterol and triglycerides [35]. Moreover, high levels of
DNA adducts were found in heart tissue from patients with severe
coronary artery disease, especially among smokers [36]. Further-
more, these molecular end-points appear to have a critical role
for disease progression and clinical outcome, as demonstrated by
recent ﬁnding on survival of patients affected by severe atheroscle-
rosis after 14 years of follow-up [37].
A recent study has also shown the presence of high levels of lipid
peroxidation-derived etheno DNA adducts in human atheroscle-
rotic lesions, demonstrating the presence of both endogenous
(oxidative stress and lipid peroxidation) and exogenous (environ-
mental factors)DNAdamage inhumanatherosclertotic plaque [38].
Furthermore, recent evidence have shown that DNAdamage not
only do occur in peripheral blood cell levels patients with coronary
artery disease and acute myocardial infarction [24,39], but it also
affects the long-term clinical outcome [40].
There was also ample evidence to suggest that the telomere
dysfunction is another key molecular events in the pathogene-
sis of cardiovascular and metabolic diseases [41,42]. Telomeres are
necessary for the genomic stability and integrity, preventing chro-
mosomal fusion by cellular DNA repair processes.
Dysfunctional telomeres, can lead to genomic instability, and
telomere length is an important factor in the pathobiology of
human disease [43,44].
Progressive telomere shortening has been demonstrated in
peripheral blood cells frompatientswithmetabolic syndrome, dia-
betes mellitus, coronary heart disease and premature myocardial
infarction [11,45–47]. Importantly, accumulating data demonstrate
that both telomere shortening and DNA damage are crucial medi-
ators for vascular dysfunction by activating the DNA-damage
response pathway [48–51].
Fig. 3. Schematic representation of gene–environment interaction. Genes and envi-
ronment risk factors alone do not trigger a cardiovascular event, that only occurs
when an individual at high genetic risk enters a high-risk environment.
This pathway involves a highly complex DNA-damage response
network, able to sense the damage, then to transduce speciﬁc sig-
nals into cells, and ﬁnally to elicit appropriate cellular responses,
affecting both endothelial and vascular smooth muscle cell func-
tions [15,48–54].
If DNA damage is severe or its accumulation exceeds its elimi-
nation by DNA repair mechanisms, cellular vascular senescence or
apoptosis will occur and this, in turn, contribute to the atherogen-
esis process (Fig. 2).
At the present time, genetic instability is, thus, part of the
pathogenetic mechanism of metabolic and vascular dysfunction,
representing an additional dimension in order to better under-
standing gene–environment interactions [55].
4. Gene–environment interactions and cardiovascular
disease
Despite the progress in the vascular biology, the pathogenesis
of CVD remains complex, and has not been fully elucidated.
Speciﬁcally, understanding of the genetic basis underlying the
pathological sequelae of atherosclerotic development is one of the
major challenge in the area of vascular biology [6]. It is generally
considered that the genetics of metabolic and cardiovascular dis-
eases involves a large number of geneswith common alleles having
weak effects on disease risk, but possibly interacting with each
other and with environmental factors could act synergistically in
the pathogenesis of MS and its complications (Fig. 3) [56]. Sev-
eral well-documented environmental variables increase the risk of
metabolic syndrome and cardiovascular disease, such as dietary fat,
smoking and alcohol consumption [57–59].
The interaction of functional gene polymorphisms with envi-
ronmental factors (gene–environment interactions) may play a
substantial role in CHD risk only when an individual with a high-
risk genetic proﬁle enters a high-risk environment, will the effect
on risk be so great that premature CHD develops (Fig. 3). Indeed, a
large number of studies have shown signiﬁcant gene–environment
interactions in the etiology of obesity as well in the pathogenesis
of type 2 diabetes and CHD [60–62]. Some selected recent reports
of gene–environment interactions, which are associated with sig-
niﬁcant effects on cardiometabolic risk are described below.
5. Gene–diet interactions and metabolic syndrome
Gene–diet interactions play an important role phenotypes
related to obesity and metabolic syndrome [60,61]. In particu-
lar, peroxisome proliferator-activated receptor-gamma2 isoform
(PPAR-2) is shown to be one of the most promising candidate
genes of commonobesity,metabolic syndrome and type 2diabetes,
and an excellent example of the relevance of gene–nutrient inter-
actions [60,61,63–67]. PPAR-2 regulates adipocyte differentiation
and lipid and glucose metabolism. Several variants in the PPAR-2
gene have been reported, among them the Pro12Ala polymorphism
which is associated with increased insulin sensitivity and reduced
risk for the development of diabetes [63,64]. Presumably, it may
have a protective effect on myocardial infarction [63,64]. The Que-
bec Family Study suggest that the PPAR-2Pro12Ala polymorphism
can modulate the association between dietary fat intake and com-
ponents of the metabolic syndrome [65].
In this study it was found a higher body mass index (BMI), vis-
ceral adipose tissue area, waist circumference and fasting glucose
concentrations in Pro12 homozygotes, but these associations were
not observed among carriers of the Ala allele [65]. In addition, car-
riers of Ala allele did not respond to a higher fat diet, as did carriers
of the Pro12 allele [65].
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The ﬁndings of a recent randomised controlled trial have also
provided a strong evidence supporting the view of a gene-diet
weight-related interaction regarding the Pro12Ala polymorphism
of PPAR-2 [66]. In this study 522 subjects with impaired glucose
tolerance were randomly assigned to an intensive diet and exercise
intervention group or a control group. By year 3 of the intervention
the odds ratio for the development of type 2 diabetes in subjects
with the Ala allele was found to be twofold higher compared with
that for the Pro12Pro genotype [66]. However, within the dietary
and exercise intervention groups none of the Ala12 homozygotes
developed diabetes during the trial [66].
Gene–nutrient interactions can also be modiﬁed by other non-
nutrient environmental factors, such as physical activity. It has
been observed that the relationship of diet and activity with fast-
ing insulin level in Ala carriers is multiplicative, and fasting insulin
level is only attenuated when both dietary fatty acid composition
and physical activity are simultaneously elevated within the con-
text of type 2 diabetes risk [67]. These ﬁndings indicate, therefore,
that beneﬁcial changes in diet, increases in physical activity, and
weight loss may reverse, to some extent, the diabetogenic impact
of the Ala12 allele, possibly due to an improved insulin sensitivity.
6. Moderate alcohol consumption and cardiovascular
protection
Another example of the gene–environment relationship on risk
of metabolic syndrome and its complications is related to the
alcohol consumption. Recently, it has been reported that heavy
drinking, in particular among liquor drinkers, is associated with an
increased risk of the metabolic syndrome by inﬂuencing its com-
ponents [68].
On theotherhand,mild tomoderate alcohol consumption, espe-
cially of beer and wine, is associated with a lower prevalence of
the metabolic syndrome and with a favorable inﬂuence on serum
lipids, waist circumference, and fasting serum insulin [69]. Speciﬁ-
cally, the subjects who consumed 1–19 alcoholic drinks per month
had a 35% reduction in risk, and those who had 20 or more drinks
each month had a 66% reduction in risk of MS [69]. In addition,
recent studies suggest that light to moderate drinking may pro-
tect against the development of diabetes [70,71] This is consistent
with observations that low to moderate amounts of alcohol intake
increase insulin sensitivity [72,73]. In addition, moderate alcohol
consumption also reduce the risk of coronary artery disease and
cardiovascular mortality compared with abstention [74,75].
However, the beneﬁcial effect of moderate alcohol consump-
tion is modiﬁed by variation a functional polymorphism in alcohol
dehydrogenase type 1C (ADH1C).
At the ADH1C locus, two polymorphisms occur at amino acids
271 and349 that are innearly complete linkagedisequilibrium [76].
The 1 subunit has a 2.5-fold higher Vmax for ethanol oxidation
than that for 2 and has a prevalence of 50–60% among Caucasian
populations [76].
Moderate drinkers who are 2 2 homozygous for the slow-
oxidizing ADH1C allele have a substantially decreased risk of
myocardial infarction and coronary artery disease [77–79].
The beneﬁt from moderate alcohol consumption is mainly due
to increased HDL concentrations that protect against the develop-
ment of atherosclerosis [78]. Ethanol itself directly increases HDL
in a dose-dependent manner [80]. Thus, this polymorphisms, asso-
ciated with a slower gastric and hepatic metabolism of ethanol,
would lead to increased HDL cholesterol concentrations and
reduced cardiovascular risk. In addition, the ability of ethanol to
potently inhibit peroxynitrite-induced DNA strand breakage might
have implications for the cardiovascular protection associatedwith
moderate consumption of ethanol [81].
7. Tobacco, genes and cardiometabolic risk
Tobacco smoke exposure is the strongest known environmen-
tal risk factor for atherosclerotic vascular disease [82]. In addition,
exposure to tobacco smoke, whether by active or passive smok-
ing, is associated with at least a fourfold increase in the risk of the
metabolic syndrome among adolescents who are overweight and
at risk for overweight [83].
Moreover, cigarette smoking increases the risk for development
of microvascular as well as macrovascular complications and mor-
tality in diabetes [84]. The effect of cigarette smoking on diabetic
vascular complications involves many metabolic and biological
processes, such as endothelial injury, oxidation of low-density
lipoprotein and changes in the hemostatic system [85].
Cigarette smoking can initiate/accelerate atherogenesis either
directly by causing endothelial dysfunction, vascular smooth mus-
cle cell proliferation in the arterial wall, or indirectly by altering
other risk factors such as lipid abnormality, procoagulant status,
and oxidative stress [86–88]. Atherogenic effects of cigarette smok-
ing also could be mediated through increase in the formation of
DNA alterations by mutagens found in tobacco smoke, which, in
turn, may lead to genetic alterations in blood vessels and the heart
[26,36–38].
However, susceptibility to adverse health effects to cigarette
smoking varies signiﬁcantly from individual to individual, and only
some individuals exposed to cigarette smoke will develop disease
whilst others will not [89]. Therefore, the interaction of functional
gene polymorphisms with smoking is believed to play a substan-
tial role in individual risk to smoking exposure. During the last
years, several studies have examined the impact of gene–smoking
interactions on CVD risk [89].
For instance, there is good evidence for a signiﬁcant interac-
tion between smoking status and apolipoprotein (apoE) genotypes
on CHD risk [62]. The common isoforms of apoE, 2, 3, and 4,
are important determinants of plasma lipid concentrations, and
the 4 allele has long been recognized as a risk factor for coro-
nary heart disease [90]. In addition, smoking increases the risk of
atherosclerotic disease in patients carrying the 4 allele compared
with the non-smoking patient [91–93]. The inter-subject variabil-
ity in smoking-inducedmetabolic and vascular diseases can be also
partly mediated by genetic variants of genes that may participate
in the activation and detoxiﬁcation processes [89].
For instance, a recent cross sectional case–control analy-
sis of participants in a health screening program demonstrated
that the combined presence of glutathione S-transferase genes
(GSTT1+/GSTM1+) afforded protection against type 2 diabetes,
and the null GSTT1− genotype or the combinations of the null
GSTT1− and/or GSTM1− genotypes were independent risk factors
for development of type 2 diabetes [94]. Furthermore, the GST null
genotypes and the current-smoking status were interactively asso-
ciated with the incidence of type 2 diabetes [94].
The genetic absence of the GSTT1 enzyme has been also asso-
ciated with the progression of diabetic retinopathy as well as with
an increased cardiovascular morbidity and mortality in patients
with type 2 diabetes [95]. Indeed, several studies have investigated
the effect between cigarette smoke and GSTM1 and GSTT1 deleted
genes on atherosclerotic risk [96–105]. Interestingly, a recent study
showed that the adverse effect of oxidative DNA damage on sur-
vival of patients with severe atherosclerosis was mainly exerted in
subjects bearing either the GSTM1 or the GSTT1 deletion [37].
Overall, these studies show that deleted GSTT1− and GSTT1−
polymorphisms contribute to development of atherosclerosis,
especially among smokers [96–105].
Interestingly a recent large case–control study investigated
the possible interplay between smoking habits, cruciferous veg-
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etable consumption, GST genotypes and myocardial infarction
[106].
High consumption of cruciferous vegetables, a major dietary
source of antioxidant isothiocyanates, might be a possible defense
mechanism against oxidative damage, thus lowering CVD risk
[107,108]. However, consumption of cruciferous vegetables was
associated with a lower risk of myocardial infarction among per-
sons with the functional GSTT-1 gene, but not among those with
theGSTT-1deleted genotype [106]. In addition, theprotective effect
among those with the GSTT1-1 gene was greater for current smok-
ers than for nonsmokers [106]. These ﬁndings strongly suggest that
inter-individual variations in enzymes involved in detoxiﬁcation of
xenobiotics and reactive oxygen species may an essential role in
the development of CVD and contribute to the emergent ﬁeld of
“environmental cardiology” [109].
8. The emerging discipline of “environmental cardiology”
The idea that the environment signiﬁcantly inﬂuences CVD is
not new, however, little is known in regard to how various drugs,
chemicals, and pollutants affect CVD [109]. At the present time,
a clear role of environmental toxins in affecting heart disease is
beginning to emerge [109,110].
In addition to tobacco smoke, certain carcinogenic environ-
mental agents, including arsenic, dioxin and ionizing radiation
exposures, have been described to be proven atherogens [26,111].
Recently, epidemiological studies have also shown that chronic
accumulation of low concentrations of environmental pollutants
within the body is associated with the prevalence of insulin resis-
tance, metabolic syndrome and diabetes [112–115].
Furthermore, it is increasingly being recognized that air
pollution exposure is a risk factor for the development of spe-
ciﬁc cardiac events [116], including life-threatening arrhythmia
[117,118] and myocardial infarction [119]. However, the mech-
anisms of the vascular injury and proatherogenic effects from
environmental toxins are not are not fully understood. The many
mechanisms of adverse cardiovascular effects are believed to
involve inﬂammation and oxidative stress [109,110,120]. In fact,
recent data have shown that both short-term and long-term
exposures are associated with increased levels of inﬂammatory
markers [121,122], and that people with MS have a higher degree
of inﬂammatory responses to ambient air pollution [123]. In
particular, long-term exposure to particulate air pollution may
contributes to systemic oxidative stress, inﬂammation, progres-
sion of atherosclerosis, and risk of ischemic heart disease
and death [124]. Short-term exposure may contribute to
complications of atherosclerosis, such as plaque vulnera-
bility, thrombosis, and acute ischemic events, especially
among patients with underlying coronary artery disease
[125].
Furthermore, the results from animal experimental models and
in vitro toxicological research have shown that toxicant exposure
induces several types of adverse vascular effects, including cyto-
toxicity, DNA damage and apoptosis [126–128].
Therefore, exposure to environmental toxicants may play a role
in the onset and progression of atherosclerosis by inducing somatic
mutation, resembling a benign tumor derived from themutation of
vascular cells [26,36–38].
Consequently, individual genetic differences in the ability to
metabolize toxicants or repairDNAdamagemay result in adifferent
susceptibility towards the environmental toxicants and, therefore,
increase the risk of developing exposure-related disease [129–131].
However, the link between the individual susceptibility to envi-
ronmental toxicants and the risk of metabolic and cardiovascular
diseases is very poorly documented.
9. Concluding remarks and future perspectives
Despite of remarkable progress, in the management of the “tra-
ditional” risk factors, CVD remains a major cause of morbidity
and mortality worldwide. The metabolic syndrome is particularly
important because its prevalence has increased dramatically in
recent years, and it is a risk factors for both CVDand type 2diabetes.
The dietary modiﬁcation and increased physical activity are
though to be the most effective preventive strategies for the
metabolic syndrome in order to prevent the development of dia-
betes mellitus and cardiovascular disease.
Anyway, it is clear that identifying the molecular mechanisms
and risk factors ofMSwill lead to better understanding of its patho-
genesis and complications.
Actually, there is growing evidence to indicate that oxidative
damage to DNA may represent an important link between
metabolic syndrome, diabetes mellitus, inﬂammation and
atherosclerosis. However, the role of DNA-damage attention
remains a poorly understood process in the pathogenesis of CVD.
In particular, establishing conclusively whether DNA damage plays
a causative role in atherosclerosis development, thrombosis, and
plaque rupture still remains to be established. Studies focusing
on the DNA repair mechanisms and use of gene-targeted animal
models exhibiting tissue-speciﬁc alterations in the major DNA
repair pathways could be important for determining whether
DNA damage plays a causative role or is secondary effect resulting
directly from an increased oxidative stress. Clinical research must
seek to deﬁne whether reduce DNA damage may be a new phar-
macological strategy for cardiovascular risk prevention in patients
with metabolic syndrome.
Finally, compelling evidence indicate that an interplay of both
environmental and common genetic factors can dramatically
impact on the development of the metabolic syndrome, type 2 dia-
betes and CVD. However, additional studies are required in order
to better deﬁne genotype–phenotype relationships and, further,
elucidatekeypathways inmetabolic andcardiovascularpathophys-
iology.
For instance, further studies of individual susceptibility to
environmental toxicants are needed in order to understand the
putative biological mechanisms linking environmental toxicants to
atherosclerotic vascular diseases.
Further research will require very large sample size, a bet-
ter assessment of environmental exposure and robust genetic
approaches, such as the use of high-throughput genotyping plat-
forms, in order to improve the understanding in gene–environment
interactions and their role in CVD risk.
These advances will be particularly relevant for improving car-
diovascular risk stratiﬁcation and conceiving the development of
“personalized intervention program”.
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